Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2018 2
2020 2
2021 3
2023 6
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

12 results

Results by year

Filters applied: . Clear all
Page 1
Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer.
Agnelli G, Becattini C, Meyer G, Muñoz A, Huisman MV, Connors JM, Cohen A, Bauersachs R, Brenner B, Torbicki A, Sueiro MR, Lambert C, Gussoni G, Campanini M, Fontanella A, Vescovo G, Verso M; Caravaggio Investigators. Agnelli G, et al. N Engl J Med. 2020 Apr 23;382(17):1599-1607. doi: 10.1056/NEJMoa1915103. Epub 2020 Mar 29. N Engl J Med. 2020. PMID: 32223112 Clinical Trial.
The Frequency of Specific KRAS Mutations, and Their Impact on Treatment Choice and Survival, in Patients With Metastatic Colorectal Cancer.
Fernández Montes A, Alonso Orduña V, Asensio Martínez E, Rodríguez Salas N, Torres E, Cacho Lavín D, Rodríguez Alonso RM, Falcó E, Oliva JC, Cirera L, García Gómez J, Pericay C. Fernández Montes A, et al. Among authors: cacho lavin d. Oncologist. 2023 Oct 3;28(10):e902-e909. doi: 10.1093/oncolo/oyad117. Oncologist. 2023. PMID: 37141400 Free PMC article.
The AGAMENON-SEOM model for prediction of survival in patients with advanced HER2-positive oesophagogastric adenocarcinoma receiving first-line trastuzumab-based therapy.
Jimenez-Fonseca P, Foy V, Raby S, Carmona-Bayonas A, Macía-Rivas L, Arrazubi V, Cacho Lavin D, Hernandez San Gil R, Custodio A, Cano JM, Fernández Montes A, Mirallas O, Macias Declara I, Vidal Tocino R, Visa L, Limón ML, Pimentel P, Martínez Lago N, Sauri T, Martín Richard M, Mangas M, Gil Raga M, Calvo A, Reguera P, Granja M, Martín Carnicero A, Hernández Pérez C, Cerdá P, Gomez Gonzalez L, Garcia Navalon F, Pacheco Barcia V, Gutierrez Abad D, Ruiz Martín M, Weaver J, Mansoor W, Gallego J. Jimenez-Fonseca P, et al. Among authors: cacho lavin d. Ther Adv Med Oncol. 2023 Mar 4;15:17588359231157641. doi: 10.1177/17588359231157641. eCollection 2023. Ther Adv Med Oncol. 2023. PMID: 36895850 Free PMC article.
Efficacy and safety of chemotherapy in young patients with advanced gastroesophageal adenocarcinoma: data from the Spanish AGAMENON-SEOM registry.
Pérez-Wert P, Custodio A, Jimenez-Fonseca P, Carmona-Bayonas A, Lecumberri A, Cacho Lavin D, Losantos García I, Fernández Montes A, Cano JM, Limón ML, Hernández San Gil R, Diez M, Vidal Tocino R, Macías Declara I, Visa L, Pimentel Cáceres P, Gil Raga M, Martínez Moreno E, Sauri T, Martín Richard M, Granja M, Cerdà P, Gómez González L, Mérida-García A, Ruiz Martín M, Gallego J; AGAMENON-SEOM study group. Pérez-Wert P, et al. Among authors: cacho lavin d. Gastric Cancer. 2024 Jan;27(1):131-145. doi: 10.1007/s10120-023-01443-9. Epub 2023 Nov 15. Gastric Cancer. 2024. PMID: 37964032
Real-World Outcomes in Patients with Metastatic Colorectal Cancer in Spain: The RWD-ACROSS Study.
Pericay C, Fernández Montes A, Alonso Orduña V, Macias Declara I, Asensio Martínez E, Rodríguez Salas N, Torres E, Cacho Lavín D, Rodríguez Alonso RM, Falcó E, Oliva JC, Cirera L. Pericay C, et al. Among authors: cacho lavin d. Cancers (Basel). 2023 Sep 17;15(18):4603. doi: 10.3390/cancers15184603. Cancers (Basel). 2023. PMID: 37760572 Free PMC article.
Immune checkpoint inhibitor-associated thrombosis in patients with bladder and kidney cancer: a study of the Spanish Society of Medical Oncology (SEOM) thrombosis and cancer group.
Sánchez Cánovas M, Fernández Garay D, Adoamnei E, Guirao García E, López Robles J, Cacho Lavin D, Martínez de Castro E, Campos Balea B, Garrido Fernández A, Fernández Pérez I, Ferrández Arias A, Suarez N, Quintanar Verduguez T, Lobo de Mena M, Rodríguez L, Gutierrez D, Martín Fernández de Soiginie AM, García Adrián S, Ferrer Pérez AI, Delgado Heredia MJ, Muñoz Lerma A, Luque R, Mazariegos Rubí M, Rúperez Blanco AB, García Escobar I, Mendiola J, Muñoz Martín AJ. Sánchez Cánovas M, et al. Among authors: cacho lavin d. Clin Transl Oncol. 2023 Oct;25(10):3021-3031. doi: 10.1007/s12094-023-03171-z. Epub 2023 Apr 10. Clin Transl Oncol. 2023. PMID: 37036596 Free PMC article.
Validation of the CoVID-TE model as a tool to predict thrombosis, bleeding, and mortality in the oncology patient with Sars-Cov-2 infection: a study by the SEOM cancer and thrombosis group.
Sánchez Cánovas M, Fernández Garay D, Gómez Martínez F, Brozos Vázquez E, Lobo de Mena M, García Adrián S, Pacheco-Barcía V, Cacho Lavin D, Martínez de Castro E, Martín Fernández de Soignie AM, Martínez E, Rúperez Blanco AB, García Escobar I, Salvador Coloma C, Blaya Boluda N, Guirao García ME, Gambín Arroniz M, Muñoz Martín AJ. Sánchez Cánovas M, et al. Among authors: cacho lavin d. Clin Transl Oncol. 2024 Jan;26(1):171-177. doi: 10.1007/s12094-023-03233-2. Epub 2023 Jun 10. Clin Transl Oncol. 2024. PMID: 37301805 Free PMC article.
Is advanced esophageal adenocarcinoma a distinct entity from intestinal subtype gastric cancer? Data from the AGAMENON-SEOM Registry.
Alvarez-Manceñido F, Jimenez-Fonseca P, Carmona-Bayonas A, Arrazubi V, Hernandez R, Cano JM, Custodio A, Pericay Pijaume C, Aguado G, Martínez Lago N, Sánchez Cánovas M, Cacho Lavin D, Visa L, Martinez-Torron A, Arias-Martinez A, López F, Limón ML, Vidal Tocino R, Fernández Montes A, Alsina M, Pimentel P, Reguera P, Martín Carnicero A, Ramchandani A, Granja M, Azkarate A, Martín Richard M, Serra O, Hernández Pérez C, Hurtado A, Gil-Negrete A, Sauri T, Morales Del Burgo P, Gallego J. Alvarez-Manceñido F, et al. Among authors: cacho lavin d. Gastric Cancer. 2021 Jul;24(4):926-936. doi: 10.1007/s10120-021-01169-6. Epub 2021 Mar 2. Gastric Cancer. 2021. PMID: 33651195
External validity of clinical trials with diverse trastuzumab-based chemotherapy regimens in advanced gastroesophageal adenocarcinoma: data from the AGAMENON-SEOM registry.
Jimenez-Fonseca P, Carmona-Bayonas A, Martinez-Torron A, Alsina M, Custodio A, Serra O, Cacho Lavin D, Limón ML, Sauri T, López F, Visa L, Granja M, Martínez Lago N, Arrazubi V, Vidal Tocino R, Hernandez R, Aguado G, Cano JM, Martín Carnicero A, Mangas M, Pimentel P, Fernández Montes A, Macias Declara I, Longo F, Ramchandani A, Martín Richard M, Hurtado A, Azkarate A, Hernández Pérez C, Serrano R, Gallego J; AGAMENON-SEOM study group. Jimenez-Fonseca P, et al. Among authors: cacho lavin d. Ther Adv Med Oncol. 2021 Jun 17;13:17588359211019672. doi: 10.1177/17588359211019672. eCollection 2021. Ther Adv Med Oncol. 2021. PMID: 34211587 Free PMC article.
12 results